Blood replacement with nanobiotechnologically engineered hemoglobin and hemoglobin nanocapsules

Area of Science:

• Biotechnology
• Nanomedicine
• Hematology

Background:

• Donor red blood cells (RBCs) require typing, cross-matching, and short-term refrigeration.
• Blood substitutes offer pathogen safety and immediate usability in emergencies.
• Current limitations of donor RBCs necessitate the development of artificial oxygen carriers.

Purpose of the Study:

• To review the development of engineered hemoglobin (Hb) and artificial red blood cells (RBCs).
• To highlight advancements in blood substitute technology using nanobiotechnology.
• To explore the potential of artificial RBCs for clinical applications.

Main Methods:

• First-generation: Glutaraldehyde crosslinking of Hb into soluble polyhemoglobin (PolyHb).
• Second-generation: Nanobiotechnology assembly of PolyHb with antioxidants (superoxide dismutase [SOD] and catalase [CAT]).
• Third-generation: Encapsulation of Hb in lipid vesicles or biodegradable polymers (e.g., PEG-PLA) to create complete artificial RBCs.

Main Results:

• Engineered Hb (PolyHb) has shown clinical efficacy.
• Second-generation PolyHb-CAT-SOD complexes offer enhanced protection against oxidative stress.
• Third-generation artificial RBCs aim for extended circulation times using nanovesicle or polymer-based systems.

Conclusions:

• Blood substitutes and artificial RBCs represent significant advancements over traditional blood transfusions.
• Nanotechnology plays a crucial role in developing next-generation blood substitutes with improved safety and efficacy.
• Further research into artificial RBCs promises to revolutionize emergency medicine and transfusion therapy.